Roche Holding AG (ROG.S)
14 Dec 2018
* SAYS PRIME DESIGNATION GRANTED BY EUROPEAN MEDICINES AGENCY FOR ROCHE’S RISDIPLAM FOR TREATMENT OF SPINAL MUSCULAR ATROPHY (SMA) Source text: https://www.roche.com/media/releases/med-cor-2018-12-17.htm Further company coverage:
Dec 14 The U.S. Food and Drug Administration on Friday approved South Korean drugmaker Celltrion Inc's biosimilar to Roche Holding AG's blockbuster breast cancer treatment, Herceptin.
A panel of European Medicines Agency (EMA) on Friday recommended approval for Pfizer Inc's Zirabev, a cheaper version to Roche Holding AG's leading cancer drug Avastin.
Dec 14 A panel of European Medicines Agency (EMA) on Friday recommended approval for Pfizer Inc's Zirabev, a cheaper version to Roche Holding AG's leading cancer drug Avastin.
BRIEF-Roche Collaborates With Merck To Develop Companion Diagnostic Test To Identify Patients Eligible For Anti-Pd-1 Therapy
* ROCHE TO DEVELOP COMPANION DIAGNOSTIC TEST TO HELP IDENTIFY PATIENTS ELIGIBLE FOR ANTI-PD-1 THERAPY BASED ON BIOMARKER EXPRESSION, NOT LOCATION, OF SOLID TUMORS
Drugmaker Gilead Sciences Inc on Monday named Roche Holding AG's Daniel O'Day as its new chief executive, tapping an industry veteran to fill a management vacuum.
* William Anderson to replace O'Day as Roche Pharmaceuticals CEO
* DANIEL O'DAY, CEO ROCHE PHARMACEUTICALS AND MEMBER OF CORPORATE EXECUTIVE COMMITTEE, WILL BE STEPPING DOWN FROM HIS ROLE AS OF 31 DECEMBER 2018
Dec 9 Drugmaker Gilead Sciences Inc will name Roche Holding AG executive Daniel O'Day as its new chief executive officer, according to a source familiar with the matter.
Swiss drugmaker Roche Holding AG said on Thursday that its Tecentriq immunotherapy in combination with Avastin and chemotherapy won U.S. Food and Drug Administration approval as a first-line treatment for a type of lung cancer.